Exact Mass: 501.2951044
Exact Mass Matches: 501.2951044
Found 500 metabolites which its exact mass value is equals to given mass value 501.2951044
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Fexofenadine
C32H39NO4 (501.28789340000003)
Fexofenadine is an antihistamine drug used in the treatment of hayfever and similar allergy symptoms. It was developed as a successor of and alternative to terfenadine, an antihistamine with potentially fatal contraindications. Fexofenadine, like other second-generation antihistamines, does not readily enter the brain from the blood, and so causes less drowsiness than first generation histamine receptor antagonists; Fexofenadine hydrochloride (brand names include Allegra and Telfast) is an antihistamine drug used in the treatment of hayfever and similar allergy symptoms. It was developed as a successor of and alternative to terfenadine, an antihistamine with potentially fatal contraindications. Fexofenadine, like other second generation antihistamines, does not readily enter the brain from the blood, and so causes less drowsiness than first-generation histamine-receptor antagonists. R - Respiratory system > R06 - Antihistamines for systemic use > R06A - Antihistamines for systemic use D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist D018926 - Anti-Allergic Agents Fexofenadine (MDL-16455) is an orally active and nonsedative H1 receptor antagonist. Fexofenadine can be used in allergic rhinitis and chronic idiopathic urticarial research[1][2][3].
Avasimibe
C29H43NO4S (501.2912638000001)
D065693 - Cytochrome P-450 Enzyme Inducers > D065701 - Cytochrome P-450 CYP3A Inducers C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent Avasimibe (CI-1011; PD-148515) is an orally active acyl coenzyme A-cholesterol acyltransferase (ACAT; also called SOAT)) inhibitor with IC50s of 24 and 9.2 μM for ACAT1 and ACAT2, respectively[1]. Avasimibe can be used for the research of prostate cancer[2].
LysoPE(0:0/20:4(5Z,8Z,11Z,14Z))
C25H44NO7P (501.28552440000004)
LysoPE(0:0/20:4(5Z,8Z,11Z,14Z)) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms. [HMDB] LysoPE(0:0/20:4(5Z,8Z,11Z,14Z)) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms.
LysoPE(0:0/20:4(8Z,11Z,14Z,17Z))
C25H44NO7P (501.28552440000004)
LysoPE(0:0/20:4(8Z,11Z,14Z,17Z)) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms. [HMDB] LysoPE(0:0/20:4(8Z,11Z,14Z,17Z)) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms.
LysoPE(20:4/0:0)
C25H44NO7P (501.28552440000004)
LysoPE(20:4(5Z,8Z,11Z,14Z)/0:0) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms. [HMDB] LysoPE(20:4(5Z,8Z,11Z,14Z)/0:0) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms.
LysoPE(20:4(8Z,11Z,14Z,17Z)/0:0)
C25H44NO7P (501.28552440000004)
LysoPE(20:4(8Z,11Z,14Z,17Z)/0:0) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms. [HMDB] LysoPE(20:4(8Z,11Z,14Z,17Z)/0:0) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms.
Avasimibe
C29H43NO4S (501.2912638000001)
Glycerophospho-N-Arachidonoyl Ethanolamine
C25H44NO7P (501.28552440000004)
fexofenadine
C32H39NO4 (501.28789340000003)
R - Respiratory system > R06 - Antihistamines for systemic use > R06A - Antihistamines for systemic use D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist CONFIDENCE standard compound; EAWAG_UCHEM_ID 3019 D018926 - Anti-Allergic Agents Fexofenadine (MDL-16455) is an orally active and nonsedative H1 receptor antagonist. Fexofenadine can be used in allergic rhinitis and chronic idiopathic urticarial research[1][2][3].
(2S)-3-Methyl-2-[(2R,2R,6S,7R,8aS)-4,6,7-trihydroxy-2,5,5,8a-tetramethyl-6-oxo-3,4,4a,5,6,6,7,8,8,8a-decahydro-2H-spiro[furo[2,3-E]isoindole-2,1-naphthalen]-7(3H)-yl]butanoic acid
Phosphatidylethanolamine lyso 20:4
C25H44NO7P (501.28552440000004)
His Ala Phe Lys
C24H35N7O5 (501.26995400000004)
Val Arg Ile Asp
Val Asp Ile Arg
Ala Phe His Lys
C24H35N7O5 (501.26995400000004)
Arg Ala Gln Lys
C28H39NO7_Spiro[2H-furo[2,3-e]isoindole-2,1(2H)-naphthalene]-7(3H)-acetic acid, 3,4,4a,5,6,6,7,8,8,8a-decahydro-4,6,7-trihydroxy-2,5,5,8a-tetramethyl-alpha-(1-methylethyl)-6-oxo-, (alphaS,2R,2R,6S,7R,8aS)
(2S)-2-[(2R,3S,7R,8R,8aS)-2,3,4-trihydroxy-4,4,7,8a-tetramethyl-6-oxospiro[2,3,4a,5,6,7-hexahydro-1H-naphthalene-8,2-3,8-dihydrofuro[2,3-e]isoindole]-7-yl]-3-methylbutanoic acid
2-((3R)-3-((3R,5S,7R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)butanamido)ethane-1-sulfonic acid
C25H43NO7S (501.27600880000006)
Ala Phe Lys His
C24H35N7O5 (501.26995400000004)
Ala His Phe Lys
C24H35N7O5 (501.26995400000004)
Ala His Lys Phe
C24H35N7O5 (501.26995400000004)
Ala Ile Ile Trp
Ala Ile Leu Trp
Ala Ile Trp Ile
Ala Ile Trp Leu
Ala Lys Phe His
C24H35N7O5 (501.26995400000004)
Ala Lys His Phe
C24H35N7O5 (501.26995400000004)
Ala Lys Gln Arg
Ala Lys Arg Gln
Ala Leu Ile Trp
Ala Leu Leu Trp
Ala Leu Trp Ile
Ala Leu Trp Leu
Ala Gln Lys Arg
Ala Gln Gln Arg
Ala Gln Arg Lys
Ala Gln Arg Gln
Ala Arg Lys Gln
Ala Arg Gln Lys
Ala Arg Gln Gln
Ala Trp Ile Ile
Ala Trp Ile Leu
Ala Trp Leu Ile
Ala Trp Leu Leu
Asp Ile Arg Val
Asp Ile Val Arg
Asp Leu Arg Val
Asp Leu Val Arg
Asp Arg Ile Val
Asp Arg Leu Val
Asp Arg Val Ile
Asp Arg Val Leu
Asp Val Ile Arg
Asp Val Leu Arg
Asp Val Arg Ile
Asp Val Arg Leu
Glu Ile Ile Lys
Glu Ile Ile Gln
Glu Ile Lys Ile
Glu Ile Lys Leu
Glu Ile Leu Lys
Glu Ile Leu Gln
Glu Ile Gln Ile
Glu Ile Gln Leu
Glu Lys Ile Ile
Glu Lys Ile Leu
Glu Lys Leu Ile
Glu Lys Leu Leu
Glu Leu Ile Lys
Glu Leu Ile Gln
Glu Leu Lys Ile
Glu Leu Lys Leu
Glu Leu Leu Lys
Glu Leu Leu Gln
Glu Leu Gln Ile
Glu Leu Gln Leu
Glu Gln Ile Ile
Glu Gln Ile Leu
Glu Gln Leu Ile
Glu Gln Leu Leu
Glu Arg Val Val
Glu Val Arg Val
Glu Val Val Arg
Phe Ala His Lys
C24H35N7O5 (501.26995400000004)
Phe Ala Lys His
C24H35N7O5 (501.26995400000004)
Phe His Ala Lys
C24H35N7O5 (501.26995400000004)
Phe His Lys Ala
C24H35N7O5 (501.26995400000004)
Phe Lys Ala His
C24H35N7O5 (501.26995400000004)
Phe Lys His Ala
C24H35N7O5 (501.26995400000004)
Gly Asn Arg Arg
Gly Arg Asn Arg
Gly Arg Arg Asn
His Ala Lys Phe
C24H35N7O5 (501.26995400000004)
His Phe Ala Lys
C24H35N7O5 (501.26995400000004)
His Phe Lys Ala
C24H35N7O5 (501.26995400000004)
His Lys Ala Phe
C24H35N7O5 (501.26995400000004)
His Lys Phe Ala
C24H35N7O5 (501.26995400000004)
Ile Ala Ile Trp
Ile Ala Leu Trp
Ile Ala Trp Ile
Ile Ala Trp Leu
Ile Asp Arg Val
Ile Asp Val Arg
Ile Glu Ile Lys
Ile Glu Ile Gln
Ile Glu Lys Ile
Ile Glu Lys Leu
Ile Glu Leu Lys
Ile Glu Leu Gln
Ile Glu Gln Ile
Ile Glu Gln Leu
Ile Ile Ala Trp
Ile Ile Glu Lys
Ile Ile Glu Gln
Ile Ile Lys Glu
Ile Ile Gln Glu
Ile Ile Trp Ala
Ile Lys Glu Ile
Ile Lys Glu Leu
Ile Lys Ile Glu
Ile Lys Leu Glu
Ile Lys Asn Gln
Ile Lys Gln Asn
Ile Leu Ala Trp
Ile Leu Glu Lys
Ile Leu Glu Gln
Ile Leu Lys Glu
Ile Leu Gln Glu
Ile Leu Trp Ala
Ile Asn Lys Gln
Ile Asn Gln Lys
Ile Gln Glu Ile
Ile Gln Glu Leu
Ile Gln Ile Glu
Ile Gln Lys Asn
Ile Gln Leu Glu
Ile Gln Asn Lys
Ile Arg Asp Val
Ile Arg Val Asp
Ile Val Asp Arg
Ile Val Arg Asp
Ile Trp Ala Ile
Ile Trp Ala Leu
Ile Trp Ile Ala
Ile Trp Leu Ala
Lys Ala Phe His
C24H35N7O5 (501.26995400000004)
Lys Ala His Phe
C24H35N7O5 (501.26995400000004)
Lys Ala Gln Arg
Lys Ala Arg Gln
Lys Glu Ile Ile
Lys Glu Ile Leu
Lys Glu Leu Ile
Lys Glu Leu Leu
Lys Phe Ala His
C24H35N7O5 (501.26995400000004)
Lys Phe His Ala
C24H35N7O5 (501.26995400000004)
Lys His Ala Phe
C24H35N7O5 (501.26995400000004)
Lys His Phe Ala
C24H35N7O5 (501.26995400000004)
Lys Ile Glu Ile
Lys Ile Glu Leu
Lys Ile Ile Glu
Lys Ile Leu Glu
Lys Ile Asn Gln
Lys Ile Gln Asn
Lys Leu Glu Ile
Lys Leu Glu Leu
Lys Leu Ile Glu
Lys Leu Leu Glu
Lys Leu Asn Gln
Lys Leu Gln Asn
Lys Asn Ile Gln
Lys Asn Leu Gln
Lys Asn Gln Ile
Lys Asn Gln Leu
Lys Gln Ala Arg
Lys Gln Ile Asn
Lys Gln Leu Asn
Lys Gln Asn Ile
Lys Gln Asn Leu
Lys Gln Gln Val
Lys Gln Arg Ala
Lys Gln Val Gln
Lys Arg Ala Gln
Lys Arg Gln Ala
Lys Val Gln Gln
Leu Ala Ile Trp
Leu Ala Leu Trp
Leu Ala Trp Ile
Leu Ala Trp Leu
Leu Asp Arg Val
Leu Asp Val Arg
Leu Glu Ile Lys
Leu Glu Ile Gln
Leu Glu Lys Ile
Leu Glu Lys Leu
Leu Glu Leu Lys
Leu Glu Leu Gln
Leu Glu Gln Ile
Leu Glu Gln Leu
Leu Ile Ala Trp
Leu Ile Glu Lys
Leu Ile Glu Gln
Leu Ile Lys Glu
Leu Ile Gln Glu
Leu Ile Trp Ala
Leu Lys Glu Ile
Leu Lys Glu Leu
Leu Lys Ile Glu
Leu Lys Leu Glu
Leu Lys Asn Gln
Leu Lys Gln Asn
Leu Leu Ala Trp
Leu Leu Glu Lys
Leu Leu Glu Gln
Leu Leu Lys Glu
Leu Leu Gln Glu
Leu Leu Trp Ala
Leu Asn Lys Gln
Leu Asn Gln Lys
Leu Gln Glu Ile
Leu Gln Glu Leu
Leu Gln Ile Glu
Leu Gln Lys Asn
Leu Gln Leu Glu
Leu Gln Asn Lys
Leu Arg Asp Val
Leu Arg Val Asp
Leu Val Asp Arg
Leu Val Arg Asp
Leu Trp Ala Ile
Leu Trp Ala Leu
Leu Trp Ile Ala
Leu Trp Leu Ala
Met Pro Arg Val
C21H39N7O5S (501.27332440000004)
Met Pro Val Arg
C21H39N7O5S (501.27332440000004)
Met Arg Pro Val
C21H39N7O5S (501.27332440000004)
Met Arg Val Pro
C21H39N7O5S (501.27332440000004)
Met Val Pro Arg
C21H39N7O5S (501.27332440000004)
Met Val Arg Pro
C21H39N7O5S (501.27332440000004)
Asn Gly Arg Arg
Asn Ile Lys Gln
Asn Ile Gln Lys
Asn Lys Ile Gln
Asn Lys Leu Gln
Asn Lys Gln Ile
Asn Lys Gln Leu
Asn Leu Lys Gln
Asn Leu Gln Lys
Asn Asn Arg Val
Asn Asn Val Arg
Asn Gln Ile Lys
Asn Gln Lys Ile
Asn Gln Lys Leu
Asn Gln Leu Lys
Asn Arg Gly Arg
Asn Arg Asn Val
Asn Arg Arg Gly
Asn Arg Val Asn
Asn Val Asn Arg
Asn Val Arg Asn
Pro Met Arg Val
C21H39N7O5S (501.27332440000004)
Pro Met Val Arg
C21H39N7O5S (501.27332440000004)
Pro Arg Met Val
C21H39N7O5S (501.27332440000004)
Pro Arg Val Met
C21H39N7O5S (501.27332440000004)
Pro Val Met Arg
C21H39N7O5S (501.27332440000004)
Pro Val Arg Met
C21H39N7O5S (501.27332440000004)
Gln Ala Lys Arg
Gln Ala Gln Arg
Gln Ala Arg Lys
Gln Glu Ile Ile
Gln Glu Ile Leu
Gln Glu Leu Ile
Gln Glu Leu Leu
Gln Ile Glu Ile
Gln Ile Glu Leu
Gln Ile Ile Glu
Gln Ile Lys Asn
Gln Ile Leu Glu
Gln Ile Asn Lys
Gln Lys Ala Arg
Gln Lys Ile Asn
Gln Lys Leu Asn
Gln Lys Asn Ile
Gln Lys Asn Leu
Gln Lys Gln Val
Gln Lys Arg Ala
Gln Lys Val Gln
Gln Leu Glu Ile
Gln Leu Glu Leu
Gln Leu Ile Glu
Gln Leu Lys Asn
Gln Leu Leu Glu
Gln Leu Asn Lys
Gln Asn Ile Lys
Gln Asn Lys Ile
Gln Asn Lys Leu
Gln Asn Leu Lys
Gln Gln Lys Val
Gln Gln Val Lys
Gln Arg Ala Lys
Gln Arg Lys Ala
Gln Val Lys Gln
Gln Val Gln Lys
Arg Ala Lys Gln
Arg Asp Ile Val
Arg Asp Leu Val
Arg Asp Val Ile
Arg Asp Val Leu
Arg Glu Val Val
Arg Gly Asn Arg
Arg Gly Arg Asn
Arg Ile Asp Val
Arg Ile Val Asp
Arg Lys Ala Gln
Arg Lys Gln Ala
Arg Leu Asp Val
Arg Leu Val Asp
Arg Met Pro Val
C21H39N7O5S (501.27332440000004)
Arg Met Val Pro
C21H39N7O5S (501.27332440000004)
Arg Asn Gly Arg
Arg Asn Arg Gly
Arg Pro Met Val
C21H39N7O5S (501.27332440000004)
Arg Pro Val Met
C21H39N7O5S (501.27332440000004)
Arg Gln Ala Lys
Arg Gln Lys Ala
Arg Arg Gly Asn
Arg Arg Asn Gly
Arg Val Asp Ile
Arg Val Asp Leu
Arg Val Glu Val
Arg Val Ile Asp
Arg Val Leu Asp
Arg Val Met Pro
C21H39N7O5S (501.27332440000004)
Arg Val Pro Met
C21H39N7O5S (501.27332440000004)
Arg Val Val Glu
Val Asp Leu Arg
Val Asp Arg Ile
Val Asp Arg Leu
Val Glu Arg Val
Val Glu Val Arg
Val Ile Asp Arg
Val Ile Arg Asp
Val Lys Gln Gln
Val Leu Asp Arg
Val Leu Arg Asp
Val Met Pro Arg
C21H39N7O5S (501.27332440000004)
Val Met Arg Pro
C21H39N7O5S (501.27332440000004)
Val Pro Met Arg
C21H39N7O5S (501.27332440000004)
Val Pro Arg Met
C21H39N7O5S (501.27332440000004)
Val Gln Lys Gln
Val Gln Gln Lys
Val Arg Asp Ile
Val Arg Asp Leu
Val Arg Glu Val
Val Arg Leu Asp
Val Arg Met Pro
C21H39N7O5S (501.27332440000004)
Val Arg Pro Met
C21H39N7O5S (501.27332440000004)
Val Arg Val Glu
Val Val Glu Arg
Val Val Arg Glu
Val Val Val Trp
Val Val Trp Val
Val Trp Val Val
Trp Ala Ile Ile
Trp Ala Ile Leu
Trp Ala Leu Ile
Trp Ala Leu Leu
Trp Ile Ala Ile
Trp Ile Ala Leu
Trp Ile Ile Ala
Trp Ile Leu Ala
Trp Leu Ala Ile
Trp Leu Ala Leu
Trp Leu Ile Ala
Trp Leu Leu Ala
Trp Val Val Val
Glycerophospho-N-Arachidonoyl Ethanolamine
C25H44NO7P (501.28552440000004)
PE(20:4/0:0)
C25H44NO7P (501.28552440000004)
LPE(20:4)
C25H44NO7P (501.28552440000004)
1-Eicsoate
C25H44NO7P (501.28552440000004)
LPE 20:4
C25H44NO7P (501.28552440000004)
(2E,12R)-12-[[3,6-Dideoxy-4-O-(1H-indol-3-ylcarbonyl)-alpha-L-arabino-hexopyranosyl]oxy]-2-tridecenoic acid
fexofenadine
C32H39NO4 (501.28789340000003)
R - Respiratory system > R06 - Antihistamines for systemic use > R06A - Antihistamines for systemic use D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist D018926 - Anti-Allergic Agents Fexofenadine is an antihistamine drug used in the treatment of hayfever and similar allergy symptoms. It was developed as a successor of and alternative to terfenadine, an antihistamine with potentially fatal contraindications. Fexofenadine, like other second-generation antihistamines, does not readily enter the brain from the blood, and so causes less drowsiness than first generation histamine receptor antagonists; Fexofenadine hydrochloride (brand names include Allegra and Telfast) is an antihistamine drug used in the treatment of hayfever and similar allergy symptoms. It was developed as a successor of and alternative to terfenadine, an antihistamine with potentially fatal contraindications. Fexofenadine, like other second generation antihistamines, does not readily enter the brain from the blood, and so causes less drowsiness than first-generation histamine-receptor antagonists. [HMDB] Fexofenadine (MDL-16455) is an orally active and nonsedative H1 receptor antagonist. Fexofenadine can be used in allergic rhinitis and chronic idiopathic urticarial research[1][2][3].
N-arachidonoyl-sn-glycero-3-phosphoethanolamine
C25H44NO7P (501.28552440000004)
(2S)-N-[(S)-[(2S,6R)-6-[(2S)-2,3-dimethoxypropyl]-5,5-dimethyl-4-oxooxan-2-yl]-methoxymethyl]-2-hydroxy-2-[(2R,5R,6R)-2-methoxy-5,6-dimethyl-4-methylideneoxan-2-yl]acetamide
C25H43NO9 (501.29376680000007)
2,3-dihydroxypropyl 2-[[(5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoyl]amino]ethyl hydrogen phosphate
C25H44NO7P (501.28552440000004)
2-azaniumylethyl (2R)-3-hydroxy-2-[(5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoyloxy]propyl phosphate
C25H44NO7P (501.28552440000004)
2-((3R)-3-((3R,5S,7R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)butanamido)ethane-1-sulfonic acid
C25H43NO7S (501.27600880000006)
(8R,9R)-9-[[3,4-dihydro-2H-1,5-benzodioxepin-6-ylmethyl(methyl)amino]methyl]-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
(8S,9S)-9-[[3,4-dihydro-2H-1,5-benzodioxepin-6-ylmethyl(methyl)amino]methyl]-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
(8R,9R)-9-[[3,4-dihydro-2H-1,5-benzodioxepin-6-ylmethyl(methyl)amino]methyl]-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
(8S,9S)-9-[[3,4-dihydro-2H-1,5-benzodioxepin-6-ylmethyl(methyl)amino]methyl]-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
(8R,9S)-9-[[3,4-dihydro-2H-1,5-benzodioxepin-6-ylmethyl(methyl)amino]methyl]-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
(8S,9S)-9-[[3,4-dihydro-2H-1,5-benzodioxepin-6-ylmethyl(methyl)amino]methyl]-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
(8S,9R)-9-[[3,4-dihydro-2H-1,5-benzodioxepin-6-ylmethyl(methyl)amino]methyl]-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
(8S,9R)-9-[[3,4-dihydro-2H-1,5-benzodioxepin-6-ylmethyl(methyl)amino]methyl]-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
(8R,9R)-9-[[3,4-dihydro-2H-1,5-benzodioxepin-6-ylmethyl(methyl)amino]methyl]-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
(8S,9R)-9-[[3,4-dihydro-2H-1,5-benzodioxepin-6-ylmethyl(methyl)amino]methyl]-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
N-[(1S,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-4-oxanecarboxamide
N-[(1R,3R,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(2-piperidin-1-ylethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-6-yl]oxane-4-carboxamide
N-[(1R,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-4-oxanecarboxamide
(2S,3R)-10-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenylphenyl)methyl]amino]methyl]-3,4-dihydro-2H-1,5-benzoxazocin-6-one
(2S,3S)-10-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenylphenyl)methyl]amino]methyl]-3,4-dihydro-2H-1,5-benzoxazocin-6-one
N-[(4R,7S,8R)-8-methoxy-4,7,10-trimethyl-5-[4-oxanyl(oxo)methyl]-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
N-[(4R,7R,8R)-8-methoxy-4,7,10-trimethyl-5-[4-oxanyl(oxo)methyl]-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
1-(3,5-dimethyl-4-isoxazolyl)-3-[(5R,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-propyl-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-(3,5-dimethyl-4-isoxazolyl)-3-[(5S,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-propyl-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-(3,5-dimethyl-4-isoxazolyl)-3-[(5R,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-propyl-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
N-[(1R,3R,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-4-oxanecarboxamide
N-[(1S,3R,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-4-oxanecarboxamide
N-[(1S,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-4-oxanecarboxamide
N-[(1S,3R,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-4-oxanecarboxamide
(8R,9R)-9-[[3,4-dihydro-2H-1,5-benzodioxepin-6-ylmethyl(methyl)amino]methyl]-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
(8R,9S)-9-[[3,4-dihydro-2H-1,5-benzodioxepin-6-ylmethyl(methyl)amino]methyl]-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
(8S,9S)-9-[[3,4-dihydro-2H-1,5-benzodioxepin-6-ylmethyl(methyl)amino]methyl]-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
(2R,3R)-10-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenylphenyl)methyl]amino]methyl]-3,4-dihydro-2H-1,5-benzoxazocin-6-one
(2S,3S)-10-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenylphenyl)methyl]amino]methyl]-3,4-dihydro-2H-1,5-benzoxazocin-6-one
(2S,3R)-10-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenylphenyl)methyl]amino]methyl]-3,4-dihydro-2H-1,5-benzoxazocin-6-one
(2R,3R)-10-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenylphenyl)methyl]amino]methyl]-3,4-dihydro-2H-1,5-benzoxazocin-6-one
(8R,9S)-9-[[3,4-dihydro-2H-1,5-benzodioxepin-6-ylmethyl(methyl)amino]methyl]-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
(8S,9R)-9-[[3,4-dihydro-2H-1,5-benzodioxepin-6-ylmethyl(methyl)amino]methyl]-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
(8R,9S)-9-[[3,4-dihydro-2H-1,5-benzodioxepin-6-ylmethyl(methyl)amino]methyl]-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
N-[(4S,7S,8S)-8-methoxy-4,7,10-trimethyl-5-[4-oxanyl(oxo)methyl]-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
N-[(4S,7S,8R)-8-methoxy-4,7,10-trimethyl-5-[4-oxanyl(oxo)methyl]-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
N-[(4R,7R,8S)-8-methoxy-4,7,10-trimethyl-5-[4-oxanyl(oxo)methyl]-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
N-[(4S,7R,8S)-8-methoxy-4,7,10-trimethyl-5-[4-oxanyl(oxo)methyl]-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
1-(3,5-dimethyl-4-isoxazolyl)-3-[(5S,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-propyl-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-(3,5-dimethyl-4-isoxazolyl)-3-[(5S,6S,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-8-propyl-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-(3,5-dimethyl-4-isoxazolyl)-3-[(5R,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-8-propyl-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-(3,5-dimethyl-4-isoxazolyl)-3-[(5R,6S,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-8-propyl-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-(3,5-dimethyl-4-isoxazolyl)-3-[(5S,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-8-propyl-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
N-[(1R,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-4-oxanecarboxamide
[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate
C25H44NO7P (501.28552440000004)
[2-hydroxy-3-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoxy]propan-2-yl] butanoate
C25H44NO7P (501.28552440000004)
(4E,8E,12E)-3-hydroxy-2-(2-hydroxydodecanoylamino)tetradeca-4,8,12-triene-1-sulfonic acid
C26H47NO6S (501.31239220000003)
(4E,8E)-3-hydroxy-2-[[(Z)-2-hydroxytetradec-9-enoyl]amino]dodeca-4,8-diene-1-sulfonic acid
C26H47NO6S (501.31239220000003)
(E)-3-hydroxy-2-[[(4Z,7Z)-2-hydroxyhexadeca-4,7-dienoyl]amino]dec-4-ene-1-sulfonic acid
C26H47NO6S (501.31239220000003)
(4E,8E)-3-hydroxy-2-[[(Z)-2-hydroxytridec-8-enoyl]amino]trideca-4,8-diene-1-sulfonic acid
C26H47NO6S (501.31239220000003)
(4E,8E)-3-hydroxy-2-[[(Z)-2-hydroxydodec-5-enoyl]amino]tetradeca-4,8-diene-1-sulfonic acid
C26H47NO6S (501.31239220000003)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoxy]propan-2-yl] acetate
C25H44NO7P (501.28552440000004)
[(2R)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (7E,10E,13E,16E)-icosa-7,10,13,16-tetraenoate
C25H44NO7P (501.28552440000004)
[(2R)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoate
C25H44NO7P (501.28552440000004)
1-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-3-phosphoethanolamine
C25H44NO7P (501.28552440000004)
2-arachidonyl-sn-glycero-3-phosphoethanolamine
C25H44NO7P (501.28552440000004)
A 2-acyl-sn-glycero-3-phosphoethanolamine in which the acyl group is specified as (5Z,8Z,11Z,14Z)-eicosatetraenoyl (arachidonoyl).
lysophosphatidylethanolamine (20:4(8Z,11Z,14Z,17Z)/0:0)
C25H44NO7P (501.28552440000004)
A 1-acyl-sn-glycero-3-phosphoethanolamine in which the acyl group is specified as 8Z,11Z,14Z,17Z-eicosapentaenoyl (omega-3-arachidonoyl).
icas#21
A 4-O-(1H-indol-3-ylcarbonyl)ascaroside derived from (2E,12R)-12-hydroxytridec-2-enoic acid. It is a metabolite of the nematode Caenorhabditis elegans.
lysophosphatidylethanolamine 20:4
C25H44NO7P (501.28552440000004)
An acyl-sn-glycero-3-phosphoethanolamine in which the acyl group contains twenty carbons and four double bonds. If R1 is an acyl group and R2 is a hydrogen then the molecule is a 1-acyl-sn-glycero-3-phosphoethanolamine. If R1 is a hydrogen and R2 is an acyl group then the molecule is a 2-acyl-sn-glycero-3-phosphoethanolamine.
Lysophosphatidylethanolamine(20:4/0:0)
C25H44NO7P (501.28552440000004)
A lysophosphatidylethanolamine 20:4 in which the acyl group is located at position 1.
lysophosphatidylethanolamine 0:0/20:4(8Z,11Z,14Z,17Z)
C25H44NO7P (501.28552440000004)
A 2-acyl-sn-glycero-3-phosphoethanolamine in which the acyl group is specified as 8Z,11Z,14Z,17Z-eicosapentaenoyl (omega-3-arachidonoyl).
1-Arachidonoyl-sn-glycero-3-phosphoethanolamine
C25H44NO7P (501.28552440000004)
A 1-acyl-sn-glycero-3-phosphoethanolamine in which the acyl group is specified as arachidonoyl.
2-arachidonoyl-sn-glycero-3-phosphoethanolamine zwitterion
C25H44NO7P (501.28552440000004)
A 2-acyl-sn-glycero-3-phosphoethanolamine zwitterion obtained by transfer of a proton from the phosphate to the amino group of 2-arachidonoyl-sn-glycero-3-phosphoethanolamine; major species at pH 7.3.
PE(20:4)
C25H44NO7P (501.28552440000004)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
LdMePE(18:4)
C25H44NO7P (501.28552440000004)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
21,23-dihydroxy-4,6,8,10,12-pentamethyl-15-oxa-22-azaheptacyclo[12.9.3.2¹⁶,¹⁹.1¹,²¹.0⁴,²⁵.0⁷,²⁶.0⁸,¹³]nonacosa-2,5,16,18,22,28-hexaen-24-one
C32H39NO4 (501.28789340000003)
(1s,4r,5s,16s,19s,23r)-19-hydroxy-4,5,24,24-tetramethyl-11-(3-methylbut-2-en-1-yl)-25,26-dioxa-7-azaheptacyclo[21.2.1.0¹,²⁰.0⁴,¹⁹.0⁵,¹⁶.0⁶,¹⁴.0⁸,¹³]hexacosa-6(14),8,10,12,20-pentaen-22-one
C32H39NO4 (501.28789340000003)